<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04603898</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-300005614</org_study_id>
    <nct_id>NCT04603898</nct_id>
  </id_info>
  <brief_title>Oxalate Formation From Ascorbic Acid</brief_title>
  <official_title>Oxalate Formation From Ascorbic Acid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this basic research study is to determine the contribution of endogenous&#xD;
      ascorbic acid (AA) turnover to urinary oxalate excretion in both lean and obese adult&#xD;
      non-stone formers and calcium oxalate stone formers. The studies proposed will use diets of&#xD;
      known nutrient composition, a stable isotope of ascorbic acid (13C6-AA) and mass&#xD;
      spectrometric techniques to quantify ascorbic acid turnover to oxalate.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent contribution of ascorbic acid (AA) to urinary oxalate excretion</measure>
    <time_frame>Day 4</time_frame>
    <description>On the last day (Day 4) of controlled diet and 24 hours following ingestion of an oral load of carbon-13 AA (1mg/kg), urine and blood will be collected and the levels of carbon 12 and carbon 13 AA and oxalate measured to determine the percent contribution of AA metabolism to urinary oxalate excretion for each subject.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">256</enrollment>
  <condition>Kidney Stone</condition>
  <arm_group>
    <arm_group_label>Controlled Dietary Study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will consume a controlled diet (low in oxalate and ascorbic acid) for six days. After two days of equilibration, subjects will provide a blood sample and ingest an oral load of ascorbic acid (1 mg/kg) with breakfast on Day 3. The following day (Day 4), serial blood and urine collections will occur. On Days 5 through 7, subjects will complete a 24-hr urine collection and blood draw.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Low Oxalate Diet</intervention_name>
    <description>Subjects will be instructed to ingest a controlled diet low in oxalate for a total of 4 days</description>
    <arm_group_label>Controlled Dietary Study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Carbon-13 Ascorbic Acid Oral Load</intervention_name>
    <description>Subjects will be instructed to ingest 1mg/kg of carbon-13 ascorbic acid at breakfast, 2 days after initiating the low oxalate controlled diet.</description>
    <arm_group_label>Controlled Dietary Study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body Mass Index (BMI) &lt; 25 or â‰¥ 30&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
          -  For stone formers: composition of most recent stone &gt; 50% calcium oxalate, no uric&#xD;
             acid component&#xD;
&#xD;
          -  For stone formers: first time or recurrent calcium oxalate stone former with stone&#xD;
             event within the prior 3 years&#xD;
&#xD;
          -  Two 24-hour urine collections with urinary 24-hour creatinine excretion within 20% of&#xD;
             appropriate ratio of creatinine (mg) / body weigh (kg) for gender&#xD;
&#xD;
          -  Willingness to stop supplements (vitamins, Calcium (citrate or carbonate) and other&#xD;
             minerals, herbal supplements, nutritional aids, probiotics) for 2 weeks before start&#xD;
             and during study&#xD;
&#xD;
          -  Willingness to not undertake vigorous exercise during the study&#xD;
&#xD;
          -  Normal fasting blood Comprehensive Metabolic Panel (CMP)&#xD;
&#xD;
          -  Willingness to ingest menus prepared in Clinical Research Unit at University of&#xD;
             Alabama at Birmingham&#xD;
&#xD;
          -  No food allergies or intolerance to any of the foods in study menus&#xD;
&#xD;
          -  If on medications for stone prevention (e.g. thiazides, citrate supplementation&#xD;
             excluding calcium citrate), they should have been on a stable dose regimen for at&#xD;
             least 8 weeks prior to and during screening, with no changes in dosing anticipated&#xD;
             during study protocol. If on allopurinol for stone prevention, stop it for 2 weeks&#xD;
             prior to screening and this will not be administered during the study as it has&#xD;
             anti-oxidant properties.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Tobacco use&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Gout&#xD;
&#xD;
          -  Hypertension&#xD;
&#xD;
          -  Estimated Glomerular Filtration Rate (eGFR) less than 60ml/min/1.73m2&#xD;
&#xD;
          -  Primary hyperoxaluria&#xD;
&#xD;
          -  Nephrotic syndrome&#xD;
&#xD;
          -  Enteric hyperoxaluria&#xD;
&#xD;
          -  Renal tubular acidosis&#xD;
&#xD;
          -  Primary hyperparathyroidism&#xD;
&#xD;
          -  Liver disease&#xD;
&#xD;
          -  Auto-immune disorder&#xD;
&#xD;
          -  Neurogenic bladder&#xD;
&#xD;
          -  Urinary diversion&#xD;
&#xD;
          -  Bariatric surgery&#xD;
&#xD;
          -  Active malignancy or treatment for malignancy within 12 months prior to screening&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Breastfeeding/nursing individuals&#xD;
&#xD;
          -  Females of child bearing age who are not able to use an effective method of birth&#xD;
             control during the study&#xD;
&#xD;
          -  Mental/medical condition that is likely to impede successful study completion&#xD;
&#xD;
          -  Illness including flu/common cold/fever 14 days before study and during study&#xD;
&#xD;
          -  Diarrhea or other abnormal gastrointestinal event (e.g. abnormal bowel movements) 14&#xD;
             days before study or during study&#xD;
&#xD;
          -  Abnormal fasting CMP&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Knight, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Demond Wiley</last_name>
    <phone>2059343671</phone>
    <email>kidneystone@uabmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35243-3353</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Demond Wiley</last_name>
      <phone>205-934-3671</phone>
      <email>kidneystone@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>John Knight</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 21, 2020</study_first_submitted>
  <study_first_submitted_qc>October 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2020</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>John Knight</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Oxalate</keyword>
  <keyword>Calcium oxalate stones</keyword>
  <keyword>Ascorbic Acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Calculi</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

